Imbria Pharmaceuticals
Boston
About Imbria Pharmaceuticals
Imbria Pharmaceuticals develops innovative therapies that target cardiometabolic disorders by leveraging insights from cellular metabolism. The company focuses on creating medicines that aim to improve the lives of patients suffering from these conditions. By translating scientific research into practical treatments, Imbria addresses significant unmet medical needs in the cardiometabolic space. Their research efforts are directed towards understanding the underlying mechanisms of disease, which informs the development of their therapeutic candidates. Through this approach, Imbria Pharmaceuticals contributes to advancing healthcare solutions for individuals affected by cardiometabolic issues.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $147.6M
- Funding stage: Early Stage Venture
- Last round: Series B (Nov 2025)
- Website: imbria.com
- Phone: +1 617 675 4060
Industries & Categories
Biotechnology, Health Care, Life Science, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/imbria-pharmaceuticals-36210 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.